Authors' Responses

Rottier BL , van Erp CJ , Sluyter TS , Heijerman HG , Frijlink HW , Boer AH . Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv., 2009; 22:263–269.

Geller DE , Margaret Rosenfeld , David A , Waltz , Robert W , Wilmott . the AeroDose TOBI Study Group. Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest., 2003; 123:28–36.

Hubert D et al. Pharmacokineric comparison of inhaled tobramycin (TOBI) via PARI eFlow^®rapid or PARI LC^® Plus nebulizers in cystic fibrosis patients. Poster presentation at the ECFC conference in Belek, 2007. Abstract in J Cyst Fibrosis, 6,Suppl. 1:S12The full paper: Pharmacokinetics and safety of tobramycin administered by the PARI eFlow^® rapid nebulizer in cystic fibrosis has recently been published in J Cyst Fibrosis. 2009;6:332–337.]

Mitchell JP , Nagel MW , Nichols S , Nerbrink O . Laser diffractometry as a technique for rapid assessment of aerosol particle size from inhalers. J Aerosol Med., 2006; 19:409–433.

Coates AL , Green M , Leung K , Louca E , Tservistas M , Chan J , Ribeiro N , Charron M . The challenges of quantitative measurement of lung depostion using ⁹⁹Tc-DTPA from delivery systems with very different delivery times. J Aerosol Med, 2007; 20:320–329.

Coates AL , Green M , Leung K , Chan J , Ribeiro N , Louca E , Ratjen F , Charron M , Tservistas M , Keller M . Rapid pulmonary delivery of inhaled tobramycin for pseudomonas infection in cystic fibrosis. Pediatr Pulmonol, 2008; 43:753–759.

Fischer R et al. Inhalation with the PARI eFlow rapid reduces treatment time burden significantly in adult CF patients without altering lung function. Poster presentation at the ECFC conference in Belek, 2008. Abstract in J Cyst Fibrosis, 6,Suppl 1:S41.

Militz S et al. E-Flow rapid: improved lung function and patient satisfaction with more volume delivered to the lungs during inhalation therapy in cystic fibrosis. Poster presented at the ECFC conference in Prague, 2008. Abstract in J Cyst Fibrosis, 7,Suppl. 2:S67.

Bakuridze L , Andrieu V , Dupond C , Dubus JC . Does repeated disinfection of the e-Flow rapid^® nebulizer affect in vitro performance? J Cystic Fibrosis, 2007; 6:309–310.

Perkins WR et al. Aerosolization of liposomal amikacin (Arikace™) using different nebulizers: selection of the eFlow^® nebulizer. Poster presented at the NACF conference in Anaheim, 2007. Abstract in Pediatric Pulmonology, 2007; 42,Suppl. 30:356.

Müller RH , Schuhmann R . Teilchengrössenmessung in der Laborpraxis. Wissenschaftliche Verlagsgesellschaft: Stuttgart, 65–70. 1996.

Stangl R , Waldner R , Seemann S , Knoch M . In-vitro characterization of the eFlow^TM electronic inhaler. Poster 194, 14th Congress of the International Society for Aerosols in Medicine. Baltimore, 2003.

Keller M , Balcke A , Tservistas M , Bucholski A , Stempfle P , Stangl R , Knoch M . Reduced treatment time for tobramycin application by device and formulation customization. Poster 329, 17th Annual North American Cystic Fibrosis Conference. Anaheim, 2003.

Friedrichs F , Keller M , Döhmen H , Pfannenstiel C , Ledermüller R . Comparison of tobramycin serum plasma levels in 5 CF patients after inhalation via a PARI LC Plus^® nebuliser and via a eFlow^®, a novel electronic inhaler. Poster P245, 27th European Cystic Fibrosis Conference. Birmingham, 2004.

Kwong WT , Ho SL , Coates AL . Comparison of nebulized particle size distribution with Malvern laser diffraction analyzer versus Andersen cascade impactor and low-flow Marple personal cascade impactor. J Aerosol Med., 2000; 13:303–314.